Mesa Laboratories, Inc.
NASDAQMesa Laboratories heads into the post-earnings period with a sharp divergence between its cost discipline and its top-line delivery — an EPS beat so large it obscures a sales miss that investors can't ignore. The headline numbers landed this morning. Adjusted EPS came in at $3.30 against an estimate of $0.34 — a significant overshoot driven by cost management rather than revenue…
Snapshot as of 27 May 2026
Mesa Laboratories heads into the post-earnings period with a sharp divergence between its cost discipline and its top-line delivery — an EPS beat so large it obscures a sales miss that investors can't ignore. The…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MLAB — free to start on ORTEX.
Sign up for free →Open MLAB on ORTEX